Macular Degeneration Therapy Area Pipeline Report

Date: September 1, 2010
Pages: 362
Price:
US$ 1,495.00
Publisher: Life Science Analytics (LSA)
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M975EDE8482EN
Leaflet:

Download PDF Leaflet

Macular Degeneration Therapy Area Pipeline Report
Life Science Analytics', Macular Degeneration Therapy Area Pipeline Report contains detailed information on the macular degeneration drug pipeline. This report provides insight into the pipeline status of macular degeneration drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits
  • Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
  • Keep track of your competitors and partners by better understanding their product pipeline.
  • Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
  • Maintain a critical competitive advantage.
Epidemiology Report
% of Products by Phase of Development
No. of Products by Phase of Development
Marketed Products vs. Pipeline Products
Company Overview - Pipeline Projects
Legend
  Top 5 Companies in Early Stage Macular Degeneration Products
  Top 5 Companies in Late Stage Macular Degeneration Products
  Top 5 Companies in Marketed Macular Degeneration Products
Patent Expirations
Upcoming Milestones
Product Sales
Full Pipeline View
  Product Details : Unknown/Research
  Product Details : Pre Clinical
  Product Details : Phase I
  Product Details : Phase II
  Product Details : Phase III
  Product Details : On the Market
News Updates
  Intellectual Property
  Product Updates
Diabetic Macular Edema Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 129 pages
Infections Sepsis Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 74 pages
Infections Tetanus Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 114 pages
Infections Tuberculosis Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 337 pages

Ask Your Question

Macular Degeneration Therapy Area Pipeline Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: